OncoLize
"Treating Tumors from the Inside"
OncoLize is preparing for it's first human trials in pancreatic cancers and other aggressive tumor indications.
We localize the slow-delivery of well-proven drugs inside the tumor.
This concentrates drugs where they should be. With effective tumor eradication, reduction of side-effects, and keeping it Triple A: Affordable and Accessible for All.
About
OncoLize (2017) is based in Maastricht, The Netherlands with operations in Leiden and Dublin.
We develop high performance oncology products for localized and slow delivery of drugs... by injecting the drug depots inside tumors. Read more...
Technology
We use polymer-based hydrogel technology that makes new formulation development simple, scalable and affordable. Read more...
Investors
Investors seeking Impact and healthy returns… join us! Read more...
OncoLize
We have shown the concept to work
We have shown the concept to work in relevant animal models, we have first patents granted and in advanced national stages and we can scale-up these products at minimal costs. With our extensive experience in setting-up controlled delivery start-up’s we aim to exit at year 6.
That being said, we at OncoLize believe and practice that our products should have impact for global issues. We will make these products available for campaigns in Low- and Middle Income Countries through focused NGO-collaborations.
We just closed a first funding round of €1.6 millionand will soon start preparing for our Series A of € 8 million for the end of 2024…
Our Team
Meet Our Team
CEO
The company was founded by Mike de Leeuw (CEO), who previously founded InGell Labs (2010), Branching Tree (2008) and DSM BioMedical (2005) and has a track record in re-structuring and re-financing other start-up’s within the controlled release/ biomedical materials space for drug delivery and cell therapy.
CTO
Mike is joined by dr.Leo de Leede (CTO), a long-time biopharmaceutical expert using polymer-enabled drug delivery in a.o. Organon/MSD – Yamanuchi/Astellas – OctoPlus/Dr.Reddy – Branching Tree/ InGell Labs.
CSO
As of April 2023 they are joined by Helena Kelly (CSO), full time professor at RCSI and the inventor of the licensed OncoLize Technology platform.
NEWS
Things happening
with OncoLize and its partners
Our developments reported by the press.
OncoLize presents latest findings in pre-clinical pancreatic tumor treatment
5th September 2024
Drug delivery start-up OncoLize (NL) achieved a remarkable 100% survival rate and growth arrest in a PDX-mouse model using its ChemGemTM on rapidly growing human pancreatic tumors in collaboration with Leiden University Medical Center.
ChemGemTM delivers Gemcitabine directly into tumors, reducing growth and extending survival without adverse effects.
Plans include safety assessments, production scaling, and clinical trial documentation for First-in-Human trials.
12th September 2024
Pharma-tech OncoLize is pitching its recent successes in pre-clinical pancreatic cancer treatment at RESI (4-6 September), PODD (28-29 October) and Bio-Europe (4-6 November) to complete its seed round with €1.5 million in order to finalize its safety and tox studies, scale-up to cGMP grade and preprare for Clinical Trial Application. The round is supported by current shareholders in anticipation of a Series A of €10+ million to start Clinical Trials in 2026 and to expand the portfolio into other tumor diseases.
7th August 2024
The base patents covering the ChemoGellTM platform has been granted by USPTO, China PTO and JPTO. These broad base patents describe the composition-of-matter and various formulations and applications essential to the oncology business Read more…
